<DOC>
	<DOC>NCT01650129</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this trial is to investigate the safety and efficacy of biphasic insulin aspart (BIAsp) 50 (NN-X14Mix50) compared with biphasic human insulin (BHI) 50 in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Subjects with type 2 diabetes Subjects with insulin treated for at least 24 weeks HbA1c maximum 11.0% Body mass index (BMI) below 30.0 kg/m^2 Patients who have the skill of selfinjection of insulin, and are able and willing to perform selfmonitoring blood glucose (SMBG) and are able to take measures against hypoglycaemic episodes Recurrent severe hypoglycaemia Subjects with proliferative retinopathy or preproliferative retinopathy diagnosed within the last 12 weeks, or receiving photocoagulation therapy within the last one year Impaired hepatic function Impaired renal function Cardiac diseases Uncontrolled hypertension Subjects with history of severe allergic or severe hypersensitive reactions Total daily insulin dose at least 100 IU Treatment with oral hypoglycaemic agentsvwithin the last 4 weeks</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>